RLYB Rallybio Corporation

9.26
-0.14  -1%
Previous Close 9.4
Open 9.5
52 Week Low 8.06
52 Week High 25.78
Market Cap $297,523,522
Shares 32,129,970
Float 19,133,924
Enterprise Value $115,043,718
Volume 33,956
Av. Daily Volume 47,588
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
RLYB212
Fetal and neonatal alloimmune thrombocytopenia (FNAIT)
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
RLYB116
Paroxysmal nocturnal hemoglobinuria (PNH); Generalized Myasthenia Gravis (gMG)
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
RLYB211
Fetal and neonatal alloimmune thrombocytopenia (FNAIT)
Phase 1/2
Phase 1/2
Phase 1/2 data reported that treatment accelerated the elimination of HPA-1ab-positive platelets through 7 days following administration compared with placebo, noted December 1, 2021.

Latest News

  1. Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Ami Bavishi has joined as the company's Head of Investor Relations and Corporate Communications.

    Ms. Bavishi brings more than 10 years of experience to Rallybio and will be responsible for overseeing Rallybio's investor relations (IR) and communications efforts, including shaping the company's IR and communications strategies. She will report to Steven Tuch, the company's Head of Corporate Development.

    "Ami is a fantastic addition to the Rallybio team, and her IR and communications skills round out the company's already…

    Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Ami Bavishi has joined as the company's Head of Investor Relations and Corporate Communications.

    Ms. Bavishi brings more than 10 years of experience to Rallybio and will be responsible for overseeing Rallybio's investor relations (IR) and communications efforts, including shaping the company's IR and communications strategies. She will report to Steven Tuch, the company's Head of Corporate Development.

    "Ami is a fantastic addition to the Rallybio team, and her IR and communications skills round out the company's already deep talent pool," said Steven Tuch. "We look forward to tapping into her industry expertise as we continue to communicate Rallybio's mission to develop and deliver unimagined therapies to change lives for those impacted by rare diseases."

    Prior to joining Rallybio, Ms. Bavishi was Director of Investor Relations at Aerie Pharmaceuticals Inc., where she oversaw all investor relations activities. Prior to Aerie, she held positions of increasing responsibility at Burns McClellan, a life sciences investor relations and public relations firm, including Vice President of Investor Relations. At Burns McClellan, Ms. Bavishi oversaw day-to-day investor relations and communications activities for multiple biotechnology companies. Ms. Bavishi also has experience as a business development professional at U.K. Trade and Investment, the business development arm of the U.K. government, where she sourced and developed bilateral investment and trade in the U.S. and U.K. life science sectors.

    "I'm excited to join Rallybio, especially as the company seeks to make important advances of its rare disease pipeline candidates," said Ms. Bavishi. "It's an immense honor to help shape the company's communications around its bold science."

    Ms. Bavishi earned her bachelor's degree in biological sciences from Duquesne University and a master's degree in public health from The George Washington University.

    About Rallybio

    Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company's mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut's Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.

    Forward-Looking Statements

    This press release contains forward-looking statements that are based on our management's beliefs and assumptions and on currently available information. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning, Rallybio's pipeline and IR and communications strategies. The forward-looking statements in this press release are only predictions and are based largely on management's current expectations and projections about future events and financial trends that management believes may affect Rallybio's business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully initiate and conduct our planned clinical trials, including the FNAIT natural history study, and the Phase 1 and or 1b clinical trials for RLYB212 and RLYB116, and complete such clinical trials and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to identify new product candidates and successfully acquire such product candidates from third parties, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio's filings with the U.S. Securities and Exchange Commission (SEC), including Rallybio's Quarterly Report on Form 10-Q for the period ended September 30, 2021, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.

    View Full Article Hide Full Article
  2. -- First subjects dosed in Phase 1 study of RLYB212; proof-of-concept data from subsequent Phase 1b study expected 3Q 2022 --

    -- On-track to initiate Phase 1 study of RLYB116 in 1Q 2022; single dose safety, PK and PD data expected 2H 2022 --

    -- Advancing preclinical development of ENPP1 inhibitor; IND-enabling studies expected to initiate in 2H 2022 --

    -- Rallybio to present these updates at 40th Annual J.P. Morgan Healthcare Conference --

    Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today provided an update on recent accomplishments and announced expected upcoming milestones…

    -- First subjects dosed in Phase 1 study of RLYB212; proof-of-concept data from subsequent Phase 1b study expected 3Q 2022 --

    -- On-track to initiate Phase 1 study of RLYB116 in 1Q 2022; single dose safety, PK and PD data expected 2H 2022 --

    -- Advancing preclinical development of ENPP1 inhibitor; IND-enabling studies expected to initiate in 2H 2022 --

    -- Rallybio to present these updates at 40th Annual J.P. Morgan Healthcare Conference --

    Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today provided an update on recent accomplishments and announced expected upcoming milestones. The Company will present these updates at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 11:15 a.m. ET.

    "Our mission is to build Rallybio into a leading biotechnology company, with a broad and sustainable pipeline of product candidates that can transform the lives of people with severe and rare disorders and shatter expectations of what's possible," said Martin Mackay, Ph.D., Chief Executive Officer of Rallybio. "In 2021, we made meaningful progress against this goal. We announced initial data that reinforced the potential of our preventative approach to FNAIT and advanced our broader portfolio, including the C5 and ENPP1 inhibitor programs, toward the clinic."

    Dr. Mackay continued, "As we enter the new year, we are poised to build on this momentum. We recently began enrolling subjects in our Phase 1 study of RLYB212, our lead product candidate for the prevention of FNAIT, and expect to initiate a Phase 1 study of RLYB116, our C5 inhibitor for the treatment of patients with PNH and gMG, in the first quarter, with initial data from both studies expected in 2022. In parallel, we continue to seek transformative science around the globe and we look forward to further expanding our portfolio with new assets and partners that have the potential to deliver dramatically improved outcomes for patients."

    Recent Portfolio Milestones and Expected Upcoming Milestones:

    Maternal Fetal Blood Disorders

    Rallybio today announced that the first subjects have been dosed in its Phase 1 study of RLYB212, a novel human monoclonal anti-HPA-1a antibody in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The single-blind, placebo-controlled Phase 1 study is designed to evaluate the safety and pharmacokinetics (PK) of single and repeat subcutaneous doses of RLYB212 in HPA-1a negative healthy volunteers. A subsequent Phase 1b proof-of-concept study, expected to initiate in the second quarter of 2022, is designed to establish the ability of RLYB212 to rapidly eliminate transfused HPA-1a positive platelets from the circulation of HPA-1a negative healthy male volunteers. Potential proof-of-concept data from the Phase 1b study are expected in the third quarter of 2022.

    Complement Dysregulation

    Rallybio expects to initiate a Phase 1 study of RLYB116 in the first quarter of 2022. RLYB116 is a novel, potentially long-acting, subcutaneously administered inhibitor of complement factor 5, or C5, in development for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and generalized Myasthenia Gravis (gMG). Single dose safety, PK and pharmacodynamic data from this Phase 1 study are expected in the second half of 2022.

    Metabolic Disorders

    Together with its partner Exscientia, Rallybio has created and is advancing a set of potentially best-in-class development candidates targeting ENPP1 for the treatment of hypophosphatasia (HPP). The companies have completed the drug design phase and are working to select a development candidate to advance into the clinic, with investigational new drug (IND)-enabling studies expected to commence in the second half of 2022.

    Presentation at the 40th Annual J.P. Morgan Healthcare Conference

    Rallybio will webcast its presentation at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 11:15 a.m. ET. A live webcast of the presentation and subsequent question and answer session will be accessible through the Events and Presentations section of Rallybio's website. An archived replay of the webcast will be available for 30 days following the presentation.

    About Rallybio

    Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company's mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut's Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.

    Forward-Looking Statements

    This press release contains forward-looking statements that are based on our management's beliefs and assumptions and on currently available information. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning, initiation and timing of our planned clinical trials for RLYB212 and RLYB116, and the timing of the availability of data from such clinical trials, the initiation and timing of our pre-IND enabling studies for our ENPP1 inhibitor, and the timing of the availability of data from such studies. The forward-looking statements in this press release are only predictions and are based largely on management's current expectations and projections about future events and financial trends that management believes may affect Rallybio's business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully initiate and conduct our planned clinical trials, including the FNAIT natural history study, and the Phase 1 and or 1b clinical trials for RLYB212 and RLYB116, and complete such clinical trials and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to identify new product candidates and successfully acquire such product candidates from third parties, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio's filings with the U.S. Securities and Exchange Commission (SEC), including Rallybio's Quarterly Report on Form 10-Q for the period ended September 30, 2021, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.

    View Full Article Hide Full Article
  3. RLYB211, an IV-administered anti-HPA-1a antibody, demonstrates ability to rapidly and safely eliminate HPA-1a mismatched platelets up to 7 days after administration

    Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced data from its ongoing Phase 1/2 study of RLYB211 showing significant benefit over placebo. RLYB211, a plasma-derived polyclonal anti-HPA-1a antibody, is being evaluated for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. There is…

    RLYB211, an IV-administered anti-HPA-1a antibody, demonstrates ability to rapidly and safely eliminate HPA-1a mismatched platelets up to 7 days after administration

    Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced data from its ongoing Phase 1/2 study of RLYB211 showing significant benefit over placebo. RLYB211, a plasma-derived polyclonal anti-HPA-1a antibody, is being evaluated for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. There is currently no approved therapy for the prevention or treatment of FNAIT.

    Extending previous findings, the new data show that administration of RLYB211 accelerated the elimination of HPA-1ab-positive platelets through 7 days following administration compared with placebo. The study simulated a real-world treatment approach to preventing FNAIT.

    "This result reinforces our preventative approach to FNAIT for mothers and babies at-risk for this potentially life-threatening-disease," said Martin Mackay, Chief Executive Officer of Rallybio. "We are both pleased with the RLYB211 findings and excited to move into the next phase of our FNAIT program by advancing RLYB212."

    These data support Rallybio's first-in-human clinical trial of its lead candidate RLYB212, a novel human monoclonal anti-HPA-1a antibody which has the same mechanism of action as RLYB211. Data from the Phase 1/2 RLYB212 trial are anticipated mid-year 2022.

    "These new data for RLYB211 add to our understanding of how we might best safely prevent FNAIT by rapidly and completely eliminating antigen from circulation before alloimmunization can occur," said Dr. Christof Geisen, Institute of Transfusion Medicine and Immunohaematology, German Red Cross Blood Transfusion Service, key collaborator in the RLYB211 study. "With this data to inform future trials this is an important step forward for at-risk families who currently have no approved treatments or therapies to prevent maternal alloimmunization, and therefore the occurrence of FNAIT in babies."

    Consistent with previously reported data, the results from the Phase 1/2 study of RLYB211 cohort 1B showed acceptable safety and tolerability with no serious adverse events. Collectively, the RLYB211 clinical data demonstrate the sustained treatment capacity of anti-HPA-1a antibodies to cause rapid and complete elimination of mismatched platelets in study volunteers.

    RLYB211 PHASE 1/2 STUDY DESIGN

    The ongoing Phase 1/2 study is a single-blind, placebo-controlled proof-of-concept study designed to establish the dose of RLYB211 that will rapidly clear HPA-1a positive platelets transfused to HPA-1a negative healthy male participants. In this study, the elimination of transfused platelets serves as a surrogate for assessing the ability of an anti-HPA-1a antibody to drive rapid elimination of HPA-1a positive fetal platelets from an expectant mother's circulation, thereby potentially preventing HPA-1a maternal alloimmunization and the occurrence of FNAIT in fetuses and newborns.

    In cohort 1B of the ongoing placebo-controlled Phase 1/2 study, HPA-1a negative healthy male participants (n=4) were randomized 3:1 to receive either 1000 IU RLYB211 or placebo (single blind) 7 days prior to administration of HPA-1a positive platelets (10x109 dose) on Day 1. Platelet elimination was assessed at Days 1, 3, and 7.

    The study is being conducted at the Clinical Research department of the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, in Frankfurt/Main, Germany in collaboration with the Institute of Transfusion Medicine and Immunohaematology, German Red Cross (Deutsches Rotes Kreuz) Blood Transfusion Service Baden-Württemberg-Hessen gGmbH in Frankfurt/Main, Germany.

    Additional information on the RLYB211 Phase 1/2 study is available at clinicaltrialsregister.eu with EudraCT Number 2019-003459-12. Learn more about FNAIT and RLYB211 here. Rallybio intends to report additional data and analyses in a future publication or other peer-reviewed forum.

    About FNAIT

    Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. FNAIT can arise during pregnancy due to an immune incompatibility between an expectant mother and her fetus in a specific platelet antigen called human platelet antigen 1, or HPA-1. There are two predominant forms of HPA-1, known as HPA-1a and HPA-1b, which are expressed on the surface of platelets. Individuals who are homozygous for HPA-1b, meaning that they have two copies of the HPA-1b allele and no copies of the HPA-1a allele, are also known as HPA-1a negative. Upon exposure to the HPA-1a antigen, these individuals can develop antibodies to that antigen in a process known as alloimmunization. In expectant mothers, alloimmunization can occur upon mixing of fetal blood with maternal blood. When alloimmunization occurs in an expectant mother, the anti-HPA-1a antibodies that develop in the mother can cross the placenta and destroy platelets in the fetus. The destruction of platelets in the fetus can result in severely low platelet counts, or thrombocytopenia, and potentially lead to devastating consequences including miscarriage, stillbirth, death of the newborn, or severe lifelong neurological disability in those babies who survive. There is currently no approved therapy for the prevention or treatment of FNAIT.

    Our FNAIT Program

    RLYB212 and RLYB211 are investigational anti-HPA-1a antibodies in development for the prevention of FNAIT. RLYB211 is a plasma-derived polyclonal anti-HPA-1a antibody administered via intravenous bolus injection. RLYB212 is a novel human monoclonal anti-HPA-1a antibody administered via subcutaneous injection. Both RLYB211 and RLYB212 are designed to rapidly eliminate fetal HPA-1a positive platelets from the circulation of a mother who is HPA-1a negative and prevent the occurrence of maternal alloimmunization, thereby eliminating the risk of FNAIT in the fetus.

    Both product candidates have received Orphan Drug Designations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency, and Rare Pediatric Disease designations from the FDA.

    About Rallybio

    Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company's mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut's Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.

    Forward-Looking Statements

    This press release contains forward-looking statements that are based on our management's beliefs and assumptions and on currently available information. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning, the timing of our clinical trials for RLYB211 or RLYB212, the period during which the results of the trials will become available or announced, and the medical benefits of RLYB211 and RLYB212. The forward-looking statements in this press release are only predictions and are based largely on management's current expectations and projections about future events and financial trends that management believes may affect Rallybio's business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully initiate and conduct our planned clinical trials, including the FNAIT natural history study, and the Phase 1/2 clinical trials for RLYB211 or RLYB212, and complete such clinical trials and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to identify new product candidates and successfully acquire such product candidates from third parties, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio's filings with the U.S. Securities and Exchange Commission (SEC), including Rallybio's Quarterly Report on Form 10-Q for the period ended September 30, 2021, and any subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.

    View Full Article Hide Full Article
  4. Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 8:00 a.m. ET. Rallybio will also host one-on-one meetings on the same day.

    A webcast of the presentation will be accessible through the Events and Presentations section of Rallybio's website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation.

    About Rallybio

    Rallybio is a clinical-stage biotechnology company…

    Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 8:00 a.m. ET. Rallybio will also host one-on-one meetings on the same day.

    A webcast of the presentation will be accessible through the Events and Presentations section of Rallybio's website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation.

    About Rallybio

    Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company's mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut's Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.

    View Full Article Hide Full Article
  5. Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a pre-recorded fireside chat at the Jefferies London Healthcare Conference. Rallybio will also host one-on-one meetings on Thursday, November 18, 2021.

    The pre-recorded fireside chat will be available for on-demand viewing through the Events and Presentations section of Rallybio's website at www.rallybio.com, beginning Thursday, November 18, 2021 at 3:00 a.m. ET. An archived replay of the webcast will be available for 30 days following the conference.

    About Rallybio

    Rallybio…

    Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a pre-recorded fireside chat at the Jefferies London Healthcare Conference. Rallybio will also host one-on-one meetings on Thursday, November 18, 2021.

    The pre-recorded fireside chat will be available for on-demand viewing through the Events and Presentations section of Rallybio's website at www.rallybio.com, beginning Thursday, November 18, 2021 at 3:00 a.m. ET. An archived replay of the webcast will be available for 30 days following the conference.

    About Rallybio

    Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company's mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut's Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.

    View Full Article Hide Full Article
View All Rallybio Corporation News